This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 32 open trials.
In 132 locations
What is a Clinical Trial?
There are currently 32 open trials
- Daratumumab in combination with standard myeloma treatment
- Exercise in transplant eligible myeloma patients (PERCEPT)
- Daratumumab with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients
- Daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed AL amyloidosis
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Effects of an exercise programme on smouldering myeloma and MGUS
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- GMI-1271 with standard of care for the treatment of multiple myeloma
- Post authorisation study of Pomalidomide (Imnovid)
- GSK2857916 in patients who have failed prior treatment with an anti-CD38 antibody (DREAMM 2)
- MGUS research study
- AZD4573 in relapsed or refractory myeloma
- Daratumumab vs. monitoring in high risk smouldering myeloma
- Selinexor for relapsed and refractory myeloma (BOSTON)
- RO6870810 monotherapy and combination for relapsed and refractory myeloma patients
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Targeted radiotherapy for myeloma
- Observational study of presentation, treatment and outcomes in myeloma patients (INSIGHT-MM)
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- Myeloma XII (ACCoRd)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK525762 trial
Trial Title:
Daratumumab in combination with standard myeloma treatment
Treatments:
Daratumumab (Darzalex®)
Bortezomib (Velcade®)
Lenalidomide (Revlimid®)
Dexamethasone
Melphalan (Alkeran)
Prednisolone
Carfilzomib (Kyprolis® )
Myeloma stage:
Relapsed, Refractory, Newly Diagnosed
Trial phase:
II
Summary:
This trial is investigating the benefit of subcutaneous (by injection under the skin) daratumumab when used in combination with standard myeloma treatments.
Locations:
Heartlands Hospital, Birmingham;
Royal Bournemouth Hospital, Bournemouth;
Kent and Canterbury Hospital, Canterbury;
Manchester Royal Infirmary, Manchester;
Derriford Hospital, Plymouth;
Royal Stoke University Hospital, Stoke
Who can enter the study?:
Patients who are either newly diagnosed or have relapsed/refractory myeloma.
What's involved?:
Patients will be assigned to one of four treatment regimens.
Newly diagnosed myeloma patients will receive either daratumumab with bortezomib, lenalidomide or dexamethasone (D-VRd) OR daratumumab with bortezomib, melphalan, prednisone and dexamethasone (D-VMP).
Relapsed/refractory myeloma patients will receive either daratumumab with lenalidomide and dexamethasone (D-Rd) OR daratumumab with carfilzomib and dexamethasone (D-Kd).
The study will consist of three phases (screening, treatment and follow-up) and duration of study is approximately 3 years.
Patients are required to attend outpatient clinics for regular check-ups and tests. Tests will include bone marrow biopsies, blood tests, skeletal surveys and electrocardiograms (EGC).
Clinical Information
(for Medical Professionals):
This trial will evaluate the clinical benefit of subcutaneous daratumumab in combination with standard myeloma treatments.
The trial hopes to demonstrate that the addition of subcutaneous daratumumab to standard myeloma treatments improves overall response rates or very good partial response (VGPR) compared to data observed in completed phase 3 trials.
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk